Please login to the form below
Rova-T
This page shows the latest Rova-T news and features for those working in and with pharma, biotech and healthcare.
Strike three for Rova-T has AbbVie cutting its losses
Will funnel R&D money into more promising projects. AbbVie has run out of patience on its antibody-drug conjugate Rova-T after yet another failed trial in lung cancer, and ... Rova-T (rovalpituzumab tesirine) consists of an anti-DLL3 antibody linked to a
Latest news
-
European biosimilars hit AbbVie’s Humira revenues in Q4
The fate of its Rovalpituzumab Tesirine (Rova-T) also hangs in the balance after it failed in a phase 3 trial for small cell lung cancer in December.
-
Bluebird and Celgene BCMA CAR-T kicks off ASCO
well as preclinical data in the much tougher challenge of using CAR-T therapies to tackle solid tumours. ... was prompted mainly by prospects for Rova-T, an ADC that failed to hit the mark in trials earlier this year.
-
AbbVie’s upadacitinib aces phase III trial
One of those new hopefuls - Rova-T for lung cancer - failed in trials but upadacitinib and anti-IL-23 antibody risankizumab (ABBV-066) remain on track after the latter reported positive
-
AbbVie slumps on trial results for would-be blockbuster Rova-T
and remain committed to developing Rova-T for the treatment of patients with SCLC.". ... Rova-T comprises an anti-DLL3 antibody linked to a cancer-killing agent called pyrrolo-benzodiazepine.
-
AbbVie's PARP inhibitor veliparib fails to deliver
Rova-T for small cell lung cancer (SCLC) and ABT-414 for the brain cancer glioblastoma.
More from news
Approximately 2 fully matching, plus 6 partially matching documents found.
Latest Intelligence
-
Deal Watch April 2016
Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3. ... Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC)
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- How an AI algorithm might save your life
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
